Positive Report for Prothena (PRTA) from Evercore ISI


In a report released today, Joshua Schimmer from Evercore ISI upgraded Prothena (PRTA) to Buy, with a price target of $14.00. The company’s shares closed last Monday at $10.24.

According to TipRanks.com, Schimmer is a 5-star analyst with an average return of 9.5% and a 49.1% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and Stealth Biotherapeutics.

Prothena has an analyst consensus of Moderate Buy, with a price target consensus of $14.00.

See today’s analyst top recommended stocks >>

Based on Prothena’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $19.45 million. In comparison, last year the company had a GAAP net loss of $24.56 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson’s disease.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts